|
Objective: To observe intravitreal bevacizumab plus triamcinolone acetonide for diabetic macular edema (diabetic macular edema, DME) effect. METHODS: August 2009 - September 2010 hospital inpatient or outpatient diagnosis by clinical examination of 32 patients with DME, computer randomized into joint injection group, 18 patients 20, 14 cases of drug injection alone 20 eye. Joint injection group with bevacizumab 1.25mg/0.05mL, 2mg/0.05mL intravitreal triamcinolone injection in the treatment; single injection group using intravitreal injection of triamcinolone acetonide 2mg/0.05mL treatment. Follow-up observation detailed record visual acuity, macular retinal thickness (central maeular thiekness, CMT), intraocular pressure changes. Results: The visual comparison between the groups: group and individual joint injection after injection, injection drug group 1w LogMAR values ??were: 0.57 ± 0.11,0.60 ± 0.54, were significantly improved (t = 4.079, P lt; 0.001), (t = 6.496, P lt; 0.001), but there were no significant differences (t = -0.981, P = 0.333); while after injection, 1m, 2m, 3m, joint injection drug group LogMAR values ??were: 0.53 ± 0.84,0.48 ± 0.70,0.50 ± 0.73, single injection group LogMAR values ??were: 0.60 ± 0.53,0.60 ± 0.52,0.60 ± 0.87. Group there was a significant difference (t = -3.278, P = 0.003), (t = -5.739, P lt; 0.001), (t = -4.072, P lt; 0.001). CMT results showed that after injection, 1m, 2m, 3m, joint injection drug group CMT values ??were: 348.33 ± 36.66,356.88 ± 40.73,368.06 ± 40.50; single injection group CMT values ??were: 350.00 ± 27.65,358.82 ± 26.97 , 369.21 ± 26.18, at each time point between the two groups compared, no significant difference (t = -0.161, P = 0.873), (t = -0.178, P = 0.860), (t = -0.107, P = 0.916 ), at different time points after treatment than before treatment were significantly different (P lt; 0.001). IOP: After treatment, 1w, 1m, 2m, 3m joint injection drug group IOP values ??were: 16.62 ± 1.24,16.57 ± 0.91,16.91 ± 1.57,16.79 ± 1.81, a separate group of injection IOP values ??were: 16.69 ± 1.52,16.80 ± 1.16,16.39 ± 0.86,16.66 ± 1.26. 1w joint after injection injection injection group and separate groups no significant difference in IOP: 1w (t = -0.144, P = 0.804), 1m (t = -0.684, P = 0.468), 2m (t = 1.306 , P = 0.208), 3m (t = 0.265, P = 0.474), joint injection drug group and individual injection treatment group at each time point compared with before treatment were significantly different (P lt; 0.001), joint injection drug group and individual injection group after treatment than before treatment IOP IOP was increased (≤ 21mmHg). Single injection group had five in two months in visual acuity decreased again when referral, 40 eyes of three in the treatment of corneal epithelium after ld little flaky exfoliation, 6 after treatment at the injection site subconjunctival small pieces bleeding, 1w bleeding after absorption. No other ophthalmic and systemic complications. Conclusions: Intravitreal injection of bevacizumab plus triamcinolone acetonide for diabetic macular edema obvious effect. Intravitreal injection of bevacizumab plus triamcinolone acetonide is a safe, reliable, convenient and economical method for the treatment of diabetic macular edema.
|